29
Participants
Start Date
January 14, 2013
Primary Completion Date
December 1, 2013
Study Completion Date
December 1, 2013
glucose clamp
Each subject will be randomly allocated to an experimental visit sequence consisting of a hypoglycaemic glucose clamp followed by euglycaemic glucose clamp (using i.v. infusion of human soluble insulin (Actrapid®)) or vice versa separated by at least 21 days. Each visit includes an overnight stay. For each of the two conditions (euglycaemia and hypoglycaemia) cognitive performance will be assessed by a validated cognitive test
Novo Nordisk Investigational Site, Århus C
Lead Sponsor
Novo Nordisk A/S
INDUSTRY